Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: dreamer who wrote (93630)	10/14/2001 6:44:58 PM
From: Guy.	Read Replies (1) \| Respond to of 150070

>Anti-U.S. rampage kills hundreds< The conclusion from all the recent events: Every parade of blood thirst, primitive muslims in any country should be met with some bombs killing thousands of these animals. Maybe then they will understand.

To: dreamer who wrote (93630)	10/14/2001 6:46:24 PM
From: Jim Bishop	Respond to of 150070

ACAM in Fortune.com story for Monday Oct 15, ACAM on page 2 of the article on Bioterror, although they blew it in the last paragraph as it has already been announced that the program has been accelerated. fortune.com As bioterror priorities are sorted out, smallpox and anthrax are likely to get the most attention--they appear to pose the greatest risk. The bad news on smallpox: The virus may have fallen into terrorists' hands as the former Soviet Union's biowarfare program disintegrated. It is hardy, highly infectious, and fatal in about 30% of untreated cases. Routine vaccination for it ended worldwide after 1980--perhaps 20% of Americans have residual immunity from childhood inoculations. In its first few days, a smallpox infection mimics flu; telltale skin lesions typically don't appear for a week or more--plenty of time for an unsuspecting carrier to infect many others. The somewhat good news: Smallpox vaccinations before exposure confer immunity, and they can attenuate illness in susceptible people if given within four days of infection. Thus, an outbreak might be contained by rapidly vaccinating people in and around the affected area and quarantining those already infected. Currently the CDC has a stockpile of about 12 million usable doses of vaccine--not nearly enough. Last year the CDC contracted with a British firm, Acambis, to add 40 million doses of a new smallpox vaccine to the U.S. stockpile beginning in 2004. Acambis and the CDC declined to comment on whether the project would be accelerated. "I'd be very surprised if it isn't," says George Washington University microbiologist Peter Hotez, who last year co-authored an article in the Washington Post arguing that at least 100 million doses would be needed to cope with a multi-city outbreak. Lance Gordon, a former Acambis executive who is now CEO at VaxGen, a Brisbane, Calif., vaccine developer, says that as soon as initial clinical tests are completed--they're needed to show whether Acambis' manufacturing process yields a consistent product--the project could be speeded up.